SEC 13F Intelligence

Managers / Q4 2023 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$128M
Q4 2023
Positions
59
Filings on Record
39
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Birchview Capital, LP reported $128M in U.S.-listed holdings across 59 positions for Q4 2023.

The portfolio is heavily concentrated: BMY alone accounts for 28.3% of reported value.

Compared with Q3 2023, the fund opened 8 new positions and exited 1.

Portfolio Metrics

Turnover
+9.3%
vs prior filed quarter
Top-10 Concentration
+70.2%
share of reported value
Largest Position
+28.3%
Bristol Myers Squibb
New / Exited
8 / 1
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 84.7%Other: 15.3%
  • Common Stock · 84.7% · $108M
  • Other · 15.3% · $20M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CHRSCOHERUS BIOSCIENCES INCNEW+110.0K110.0K+$366,300$366,300
SWTXUSDSPRINGWORKS THERAPEUTICS INCNEW+10.0K10.0K+$365,000$365,000
BIOHAVEN PHARMACEUTICAL HOLDING CO LTDNEW+7.4K7.4K+$315,222$315,222
ZNTLZENTALIS PHARMACEUTICALS INCNEW+16.0K16.0K+$242,400$242,400
LQDALIQUIDIA CORPORATIONNEW+20.0K20.0K+$240,600$240,600
CABACABALETTA BIO INCNEW+10.0K10.0K+$227,000$227,000
CSTLCASTLE BIOSCIENCES INCNEW+10.0K10.0K+$215,800$215,800
WAVE LIFE SCIENCES LTDNEW+40.0K40.0K+$202,000$202,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM28.25%$36M702.3K
2NBIXNEUROCRINE BIOSCIENCES INChistory →COM7.98%$10M77.2K
3BIODESIX INCCOM7.27%$9M5.04M
4ACADACADIA PHARMACEUTICALS INChistory →COM5.90%$8M240.4K
5PROTHENA CORP PLCSHS4.83%$6M169.6K
6IMGNEURIMMUNOGEN INChistory →COM4.37%$6M188.0K
7QDEL*QUIDELORTHO CORPhistory →COM3.77%$5M65.2K
8OVVOVINTIV INChistory →COM2.90%$4M84.2K
9ELUTELUTIA INChistory →COM2.80%$4M1.66M
10PHRPHREESIA INChistory →COM2.08%$3M114.7K
11UTHUNITED THERAPEUTICS CORPhistory →COM1.90%$2M11.0K
12CYTKCYTOKINETICS INChistory →COM1.64%$2M25.0K
13FHTXFOGHORN THERAPEUTICS INChistory →COM1.62%$2M320.9K
14SILKUSDSILK ROAD MEDICAL INChistory →COM1.52%$2M158.1K
15INBXUSDINHIBRX INChistory →COM1.44%$2M48.4K
16MASI*MASIMO CORPhistory →COM1.40%$2M15.3K
17HROWHARROW HEALTH INChistory →COM1.32%$2M150.0K
18TXG10X GENOMICS INChistory →CL A COM1.32%$2M30.0K
19HTDCORCEPT THERAPEUTICS INChistory →COM1.27%$2M50.0K
20ALKERMES PLCSHS1.09%$1M50.0K
21ETRNUSDEQUITRANS MIDSTREAM CORPORATIOhistory →COM1.06%$1M133.1K
22ATECALPHATEC HOLDINGS INChistory →COM1.04%$1M88.0K
23AXGNAXOGEN INCCOM0.93%$1M173.0K
24STOKSTOKE THERAPEUTICS INCCOM0.87%$1M210.0K
25PTGXPROTAGONIST THERAPEUTICS INCCOM0.86%$1M48.0K
26TVTXTRAVERE THERAPEUTICS INCCOM0.86%$1M122.0K
27APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.84%$1M18.0K
28ACCELERATE DIAGNOSTICS INCCOM0.69%$882,936225.2K
29PXDEURPIONEER NATURAL RESOURCES COCOM0.67%$854,5443.8K
30DCGODOCGO INCCOM0.66%$838,500150.0K
31PGNYPROGYNY INCCOM0.64%$817,96022.0K
32ARVNARVINAS INCCOM0.48%$617,40015.0K
33KINIKSA PHARMACEUTICALS LTDCOM0.41%$526,20030.0K
344XC1KALVISTA PHARMACEUTICALS INCCOM0.38%$490,00040.0K
35XENEXENON PHARMACEUTICALS INCCOM0.36%$460,60010.0K
36BLUEBIRD BIO INCCOM0.35%$443,256321.2K
37KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.32%$406,405469.8K
38AM6AMICUS THERAPEUTICS INCCOM0.31%$397,32028.0K
39HALOHALOZYME THERAPEUTICS INCCOM0.29%$369,60010.0K
40CHRSCOHERUS BIOSCIENCES INCCOM0.29%$366,300110.0K
41SWTXUSDSPRINGWORKS THERAPEUTICS INCCOM0.29%$365,00010.0K
42BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.25%$315,2227.4K
43KROSKEROS THERAPEUTICS INCCOM0.22%$278,3207.0K
44XNCRXENCOR INCCOM0.20%$261,12912.3K
45BIODESIX INC COM RSTCOM0.20%$257,360153.7K
46CGEMCULLINAN ONCOLOGY INCCOM0.20%$255,91225.1K
47GTHXEURG1 THERAPEUTICS INCCOM0.19%$244,00080.0K
48ZNTLZENTALIS PHARMACEUTICALS INCCOM0.19%$242,40016.0K
49SRPTSAREPTA THERAPEUTICS INCCOM0.19%$241,0752.5K
50LQDALIQUIDIA CORPORATIONCOM0.19%$240,60020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.